Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 25,000 shares of the business's stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $80.17, for a total transaction of $2,004,250.00. Following the completion of the transaction, the director owned 830,073 shares of the company's stock, valued at $66,546,952.41. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Liquidia Stock Performance
LQDA stock opened at $79.47 on Thursday. Liquidia Corporation has a one year low of $12.88 and a one year high of $82.96. The firm has a market cap of $7.07 billion, a price-to-earnings ratio of 567.68 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The firm has a 50-day simple moving average of $63.33 and a two-hundred day simple moving average of $46.35.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business's revenue was up 4187.1% on a year-over-year basis. On average, equities analysts forecast that Liquidia Corporation will post 3.02 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Liquidia in the fourth quarter worth $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at $25,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia in the 3rd quarter valued at $34,000. Covestor Ltd raised its stake in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock worth $42,000 after acquiring an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company's stock worth $83,000 after acquiring an additional 4,927 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on LQDA shares. Jefferies Financial Group reaffirmed a "buy" rating and set a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. Oppenheimer set a $75.00 price objective on Liquidia in a research report on Friday, June 5th. Needham & Company LLC boosted their target price on Liquidia from $54.00 to $70.00 and gave the stock a "buy" rating in a research note on Monday, May 11th. Bank of America reaffirmed a "neutral" rating and set a $79.00 target price (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Finally, Wells Fargo & Company increased their price target on Liquidia from $51.00 to $62.00 and gave the company an "overweight" rating in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $68.88.
Read Our Latest Analysis on Liquidia
About Liquidia
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
